npj Parkinsons Disease

Papers
(The H4-Index of npj Parkinsons Disease is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Effects of Alzheimer’s genetic risk scores and CSF biomarkers in de novo Parkinson’s Disease199
Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism117
Author Correction: Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology117
Push-pull effects of basal ganglia network in Parkinson’s disease inferred by functional MRI106
Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease103
Classification of Parkinson’s disease and isolated REM sleep behaviour disorder: delineating progression markers from the sebum volatilome96
Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease94
Proinflammatory and GABA eating bacteria in Parkinson's disease gut microbiome from a meta-analysis perspective93
Differential memory enrichment of cytotoxic CD4 T cells in Parkinson’s disease patients reactive to α-synuclein92
Corneal confocal microscopy differentiates patients with secondary parkinsonism from idiopathic Parkinson’s disease92
VisionMD: an open-source tool for video-based analysis of motor function in movement disorders91
Author Correction: Synaptic loss and its association with symptom severity in Parkinson’s disease89
Cdk5 phosphorylation-induced SIRT2 nuclear translocation promotes the death of dopaminergic neurons in Parkinson’s disease87
Alpha synuclein modulates mitochondrial Ca2+ uptake from ER during cell stimulation and under stress conditions84
Differences in brain aging between sexes in Parkinson’s disease84
Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease77
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease75
Patient-centered development of clinical outcome assessments in early Parkinson disease: key priorities and advances75
Patterns of cerebellar cortex hypermetabolism on motor and cognitive functions in PD66
Association between functional gastrointestinal disorders and Parkinson’s disease in a prospective cohort study63
A systematic exploration of unexploited genes for oxidative stress in Parkinson’s disease63
EGFR phosphorylates DNAJB1 to suppress α-synuclein aggregation in Parkinson’s disease61
A versatile computational algorithm for time-series data analysis and machine-learning models59
Genetic risk and plasma biomarkers of dementia with Lewy bodies in a Chinese population59
Machine Learning in the Parkinson’s disease smartwatch (PADS) dataset59
Redefining the hypotheses driving Parkinson’s diseases research58
Advanced brain aging in Parkinson’s disease with cognitive impairment58
Unveiling early signs of Parkinson’s disease via a longitudinal analysis of celebrity speech recordings58
The experience of Anxiety for people with Parkinson’s disease56
α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular–mitral synaptic transmission56
Irisin exhibits neuroprotection by preventing mitochondrial damage in Parkinson’s disease56
Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies56
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia54
Baseline [18F]FP-CIT PET-based deep learning prediction of levodopa-induced dyskinesia in Parkinson’s disease54
Identification of PLOD3 and LRRN3 as potential biomarkers for Parkinson’s disease based on integrative analysis53
Resilience of striatal synaptic plasticity over early structural adaptations in premotor parkinsonism51
Plasma GFAP as a prognostic biomarker of motor subtype in early Parkinson’s disease51
Park7 deletion leads to sex-specific transcriptome changes involving NRF2-CYP1B1 axis in mouse midbrain astrocytes50
Reply to Matters Arising: Is congenital anosmia protective for Parkinson’s disease triggered by pathogenic entrance through the nose?49
Harmol promotes α-synuclein degradation and improves motor impairment in Parkinson’s models via regulating autophagy-lysosome pathway49
In memorium, Michael Zigmond, PhD49
Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach49
Butyrate improves abnormal sleep architecture in a Parkinson’s disease mouse model via BDNF/TrkB signaling47
Cerebrospinal fluid biomarkers in Parkinson’s disease with freezing of gait: an exploratory analysis46
Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus46
Characterization of the pathogenic α-Synuclein Variant V15A in Parkinson´s disease45
0.027829170227051